HUE055668T2 - Neuroaktív szteroidok - Google Patents

Neuroaktív szteroidok

Info

Publication number
HUE055668T2
HUE055668T2 HUE18190034A HUE18190034A HUE055668T2 HU E055668 T2 HUE055668 T2 HU E055668T2 HU E18190034 A HUE18190034 A HU E18190034A HU E18190034 A HUE18190034 A HU E18190034A HU E055668 T2 HUE055668 T2 HU E055668T2
Authority
HU
Hungary
Prior art keywords
neuroactive steroids
neuroactive
steroids
Prior art date
Application number
HUE18190034A
Other languages
English (en)
Hungarian (hu)
Inventor
Botella Gabriel Martinez
Boyd L Harrison
Albert J Robichaud
Francesco G Salituro
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of HUE055668T2 publication Critical patent/HUE055668T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE18190034A 2013-03-13 2014-03-13 Neuroaktív szteroidok HUE055668T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361779735P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
HUE055668T2 true HUE055668T2 (hu) 2021-12-28

Family

ID=51625437

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE18190034A HUE055668T2 (hu) 2013-03-13 2014-03-13 Neuroaktív szteroidok
HUE21172859A HUE072324T2 (hu) 2013-03-13 2014-03-13 Neuroaktív szteroidok és módszerek alkalmazásukra

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE21172859A HUE072324T2 (hu) 2013-03-13 2014-03-13 Neuroaktív szteroidok és módszerek alkalmazásukra

Country Status (25)

Country Link
US (6) US20160031930A1 (enExample)
EP (4) EP3461834B1 (enExample)
JP (6) JP6255082B2 (enExample)
CN (3) CN118702755A (enExample)
AU (5) AU2014243773B2 (enExample)
BR (1) BR112015022174B1 (enExample)
CA (2) CA2905359C (enExample)
CY (2) CY1120934T1 (enExample)
DK (3) DK3932932T3 (enExample)
ES (3) ES3042115T3 (enExample)
FI (1) FI3932932T3 (enExample)
HR (3) HRP20251221T1 (enExample)
HU (2) HUE055668T2 (enExample)
IL (3) IL318314A (enExample)
LT (3) LT2968369T (enExample)
MX (2) MX362544B (enExample)
PL (3) PL3461834T3 (enExample)
PT (3) PT2968369T (enExample)
RS (3) RS58166B1 (enExample)
RU (1) RU2684103C2 (enExample)
SI (3) SI2968369T1 (enExample)
SM (3) SMT202500336T1 (enExample)
TR (1) TR201817995T4 (enExample)
WO (1) WO2014160480A1 (enExample)
ZA (1) ZA201506729B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007062266A2 (en) 2005-11-28 2007-05-31 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
EP2633621B1 (en) 2010-10-27 2017-08-30 Merus Audio ApS Audio amplifier using multi-level pulse width modulation
PT2753632T (pt) 2011-09-08 2023-08-17 Sage Therapeutics Inc Esteróides neuroactivos, composições e respectivas utilizações
SMT202500336T1 (it) 2013-03-13 2025-11-10 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016007762A1 (en) 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
CN112121171A (zh) 2014-10-07 2020-12-25 萨奇治疗股份有限公司 神经活性化合物及其使用方法
JP6882996B2 (ja) * 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
AU2016289971C1 (en) * 2015-07-06 2022-12-08 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN113292623A (zh) * 2015-07-06 2021-08-24 萨奇治疗股份有限公司 孕甾醇及其使用方法
CN108135838A (zh) 2015-10-16 2018-06-08 马瑞纳斯制药公司 包含纳米粒的可注射神经类固醇制剂
JP7112331B2 (ja) * 2016-04-01 2022-08-03 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
TWI752976B (zh) * 2016-07-07 2022-01-21 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
CN109715151A (zh) 2016-08-11 2019-05-03 奥维德医疗公司 用于治疗癫痫性紊乱的方法和组合物
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CA3038900A1 (en) * 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
CN115181153A (zh) * 2016-10-18 2022-10-14 萨奇治疗股份有限公司 氧甾醇及其使用方法
CN115322238A (zh) 2016-10-18 2022-11-11 萨奇治疗股份有限公司 氧甾醇及其使用方法
CN106632565A (zh) * 2016-11-07 2017-05-10 湖南科瑞生物制药股份有限公司 一种合成胆固醇的新方法
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
WO2020260558A1 (en) 2019-06-27 2020-12-30 Phenex Pharmaceuticals Ag 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases
CN114728012A (zh) 2019-08-05 2022-07-08 马瑞纳斯制药公司 用于治疗癫痫持续状态的加奈索酮
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
IL308273A (en) * 2021-05-04 2024-01-01 Sage Therapeutics Inc Neuroactive steroids for the treatment of mild cognitive impairment associated with Parkinson's disease
WO2022261510A1 (en) 2021-06-11 2022-12-15 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
JP2024532273A (ja) * 2021-08-25 2024-09-05 セージ セラピューティクス， インコーポレイテッド ポジティブｎｍｄａモジュレート化合物及びその使用方法
WO2023049295A1 (en) * 2021-09-22 2023-03-30 Sage Therapeutics, Inc. Deuterated positive nmda-modulating compounds and methods of use thereof
WO2023083979A1 (en) * 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
JP2024544777A (ja) * 2021-12-13 2024-12-04 セージ セラピューティクス， インコーポレイテッド ハンチントン病の治療のための神経活性ステロイド
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
CN114478672B (zh) * 2022-01-27 2024-06-14 浙江仙居君业药业有限公司 一种he3286的合成方法
CN119677761A (zh) 2022-06-24 2025-03-21 萨奇治疗股份有限公司 神经活性类固醇的结晶形式
IL318308A (en) 2022-07-12 2025-03-01 Sage Therapeutics Inc Crystalline form of a neuroactive steroid
TW202508603A (zh) 2023-05-02 2025-03-01 美商賽吉醫療公司 神經活性類固醇調配物及其使用方法
WO2025227053A1 (en) * 2024-04-25 2025-10-30 Sage Therapeutics, Inc. Nmda receptor positive allosteric modulatory compositions and methods of use thereof

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2259698A (en) 1938-05-07 1941-10-21 Rare Chemicals Inc Physiologically effective substance and process of preparing same
US2594323A (en) 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US2673206A (en) 1950-06-07 1954-03-23 Schering Corp 25-ethinyl steroids
US3079385A (en) 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
JPS5324071B2 (enExample) 1974-04-30 1978-07-18
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en) 1975-10-10 1982-03-31 Hoffmann La Roche Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja) 1976-12-28 1983-09-08 帝人株式会社 ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en) * 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
JPS54163565A (en) 1978-06-09 1979-12-26 Teijin Ltd 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en) 1978-08-01 1979-11-13 Kaiser Emil T Synthesis of steroids
US4269777A (en) 1979-05-21 1981-05-26 Wisconsin Alumni Research Foundation Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en) 1980-08-13 1982-02-26 Teijin Ltd 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
JPS61254599A (ja) 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
JPS6253960A (ja) 1985-05-30 1987-03-09 Taisho Pharmaceut Co Ltd ビタミンｄ↓３の誘導体
JPS62187485A (ja) 1986-02-13 1987-08-15 Teijin Ltd ２４，２５−エポキシコレステロ−ル類の製造法
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU698834B2 (en) 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
DE4338316A1 (de) 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1038880B1 (en) * 1994-02-14 2007-10-17 Euro-Celtique S.A. Androstanes and pregnanes for allosteric modulation of GABA receptor
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5595996A (en) 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
NZ298567A (en) 1994-11-23 2000-01-28 Cocensys Inc Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment
JPH08268917A (ja) 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
EP0837874B1 (en) 1995-06-06 2004-12-15 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
RU2182909C2 (ru) 1995-06-23 2002-05-27 Ново Нордиск А/С Стероиды, способ регулирования мейоза
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
WO1997003677A1 (en) 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
WO1997042215A1 (en) 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja) 1996-06-10 1997-12-22 Teijin Ltd ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6122371A (en) 1997-07-22 2000-09-19 Atwell; Ronald C. Apparatus for protecting coin-operated telephones from vandalism and larceny
CA2331299A1 (en) 1998-05-11 1999-11-18 Novo Nordisk A/S Substituted guanidines and diaminonitroethenes, their preparation and use
ATE256144T1 (de) 1998-05-13 2003-12-15 Novo Nordisk As Verwendung von verbindungen mit der fähigkeit die meiose zu regulieren
KR20010043558A (ko) 1998-05-13 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
US8541600B2 (en) 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
CN1111167C (zh) 1999-10-22 2003-06-11 中国科学院上海有机化学研究所 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh) 1999-11-12 2003-01-08 中国科学院上海有机化学研究所 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
CA2446314C (en) * 2001-05-03 2011-02-22 The University Of Chicago Liver x receptor agonists
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
JP2005508368A (ja) 2001-11-08 2005-03-31 ザ ユニバーシティー オブ シカゴ 高コレステロール濃度に関連した疾患の治療方法
AU2002360489A1 (en) 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
PL213697B1 (pl) 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
KR101130212B1 (ko) 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
WO2004055201A2 (en) 2002-12-13 2004-07-01 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
KR101358078B1 (ko) 2004-11-01 2014-02-06 주식회사 유스팜인터내셔널 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물
CA2643732C (en) 2006-02-27 2012-08-21 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
CN101164540A (zh) 2006-08-03 2008-04-23 中山大学 海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
WO2008057468A1 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2008063128A1 (en) 2006-11-21 2008-05-29 Umecrine Ab The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
CN104892498A (zh) 2007-06-20 2015-09-09 奥斯拜客斯制药有限公司 作为纤维化抑制剂的取代的n-芳基吡啶酮
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009059239A2 (en) 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
CA2703497A1 (en) 2007-11-06 2009-05-14 N.V. Organon A method of hormone suppression in humans
JP2011505357A (ja) 2007-12-03 2011-02-24 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール
WO2009090063A1 (en) 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
EP2244577B1 (en) 2008-01-25 2012-10-31 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
EP2255818B1 (en) 2008-02-19 2018-08-22 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
SG195568A1 (en) 2008-05-09 2013-12-30 Univ Emory Nmda receptor antagonists for the treatment of neuropsychiatric disorders
CN101683348B (zh) * 2008-09-23 2012-07-04 中山大学 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
WO2010088408A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor antagonists for the treatment of neurological conditions
JP2013500986A (ja) 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓ｘ受容体アゴニスト
WO2011028794A2 (en) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2011092127A1 (en) 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP2013521307A (ja) * 2010-03-03 2013-06-10 サトリ・ファーマシューティカルズ・インコーポレイテッド 神経変性障害を治療するのに有用な化合物
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
WO2012142039A1 (en) 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
US20140335050A1 (en) 2011-05-27 2014-11-13 The General Hospital Corporation Methods, compositions, and kits for the treatment of cancer
WO2013019711A2 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
PT2753632T (pt) 2011-09-08 2023-08-17 Sage Therapeutics Inc Esteróides neuroactivos, composições e respectivas utilizações
PT2763979T (pt) 2011-10-07 2019-04-12 Takeda Pharmaceuticals Co Compostos de 1-arilcarbonil-4-oxi-piperidina úteis para o tratamento de doenças neurodegenerativas
EP2766380B1 (en) 2011-10-14 2019-04-24 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
EP2841067A4 (en) 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
US9737522B2 (en) 2012-08-09 2017-08-22 Emory University NMDA receptor modulators and uses related thereto
US20140149272A1 (en) 2012-08-17 2014-05-29 Trueex Group Llc Interoffice bank offered rate financial product and implementation
SG11201504848QA (en) 2012-12-18 2015-07-30 Univ Washington Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
CN112552364A (zh) 2013-01-23 2021-03-26 司菲埃拉制药私人有限公司 用于线粒体生物发生和与线粒体功能障碍或耗竭相关的疾病的新颖11β-羟基类固醇化合物
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
CN112057457A (zh) 2013-03-13 2020-12-11 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
SMT202500336T1 (it) 2013-03-13 2025-11-10 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
RU2019126333A (ru) 2013-04-17 2019-10-08 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
CN106456729A (zh) 2014-02-08 2017-02-22 豪夫迈·罗氏有限公司 治疗阿尔茨海默氏病的方法
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016007762A1 (en) 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
CN112121171A (zh) 2014-10-07 2020-12-25 萨奇治疗股份有限公司 神经活性化合物及其使用方法
AU2016289971C1 (en) 2015-07-06 2022-12-08 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN113292623A (zh) 2015-07-06 2021-08-24 萨奇治疗股份有限公司 孕甾醇及其使用方法
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
JP7112331B2 (ja) 2016-04-01 2022-08-03 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
TWI752976B (zh) 2016-07-07 2022-01-21 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
EP3481844B1 (en) 2016-07-11 2024-04-17 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CA3038900A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
CN115181153A (zh) 2016-10-18 2022-10-14 萨奇治疗股份有限公司 氧甾醇及其使用方法
CN115322238A (zh) 2016-10-18 2022-11-11 萨奇治疗股份有限公司 氧甾醇及其使用方法
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
AU2018288883B2 (en) 2017-06-23 2022-06-02 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives
WO2019094724A1 (en) 2017-11-10 2019-05-16 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders

Also Published As

Publication number Publication date
TR201817995T4 (en) 2019-02-21
AU2014243773A1 (en) 2015-10-01
AU2019201275B2 (en) 2020-10-15
WO2014160480A1 (en) 2014-10-02
US20220064207A1 (en) 2022-03-03
MX388210B (es) 2025-03-19
RS67266B1 (sr) 2025-10-31
CY1124629T1 (el) 2022-07-22
IL280068B1 (en) 2025-02-01
HRP20251221T1 (hr) 2025-12-05
US20180237470A1 (en) 2018-08-23
US11104701B2 (en) 2021-08-31
US20160031930A1 (en) 2016-02-04
CA2905359A1 (en) 2014-10-02
SMT201800657T1 (it) 2019-01-11
SMT202500336T1 (it) 2025-11-10
JP7317898B2 (ja) 2023-07-31
ES3042115T3 (en) 2025-11-18
IL280068A (en) 2021-03-01
CN118702755A (zh) 2024-09-27
MX362544B (es) 2019-01-24
JP2018030890A (ja) 2018-03-01
AU2019201275A1 (en) 2019-03-14
EP2968369B1 (en) 2018-08-29
RS62235B1 (sr) 2021-09-30
JP2021152086A (ja) 2021-09-30
US11905309B2 (en) 2024-02-20
MX2015012430A (es) 2016-02-03
EP3461834A1 (en) 2019-04-03
AU2021200205B2 (en) 2022-09-01
PL3461834T3 (pl) 2021-12-27
EP4643945A8 (en) 2025-12-17
CY1120934T1 (el) 2019-12-11
NZ712141A (en) 2020-10-30
NZ751196A (en) 2020-10-30
SI2968369T1 (sl) 2019-01-31
US20190127414A1 (en) 2019-05-02
RS58166B1 (sr) 2019-03-29
LT3932932T (lt) 2025-09-10
HUE072324T2 (hu) 2025-11-28
CN105246486A (zh) 2016-01-13
ZA201506729B (en) 2017-09-27
HRP20181994T1 (hr) 2019-03-08
PT3461834T (pt) 2021-09-10
JP6255082B2 (ja) 2017-12-27
PT2968369T (pt) 2018-12-05
CN112375115A (zh) 2021-02-19
ES2886506T3 (es) 2021-12-20
HRP20211300T1 (hr) 2021-11-12
ES2699445T3 (es) 2019-02-11
US20170305960A1 (en) 2017-10-26
AU2014243773B2 (en) 2018-12-13
LT3461834T (lt) 2021-10-25
SI3932932T1 (sl) 2025-10-30
FI3932932T3 (fi) 2025-10-15
EP3461834B1 (en) 2021-05-19
US10227375B2 (en) 2019-03-12
EP3932932B8 (en) 2025-11-19
EP4643945A2 (en) 2025-11-05
AU2022279366A1 (en) 2023-01-19
PL2968369T3 (pl) 2019-03-29
IL280068B2 (en) 2025-06-01
DK2968369T3 (en) 2018-12-17
SI3461834T1 (sl) 2021-11-30
RU2684103C2 (ru) 2019-04-04
LT2968369T (lt) 2018-12-27
BR112015022174A8 (pt) 2019-11-26
US20240287125A1 (en) 2024-08-29
JP2019135261A (ja) 2019-08-15
IL318314A (en) 2025-03-01
RU2019109033A (ru) 2019-05-21
WO2014160480A8 (en) 2015-01-08
EP3932932A1 (en) 2022-01-05
PL3932932T3 (pl) 2025-11-24
EP3932932B1 (en) 2025-07-16
IL241301B (en) 2021-01-31
BR112015022174A2 (pt) 2017-07-18
JP2022180606A (ja) 2022-12-06
JP2025120299A (ja) 2025-08-15
CN105246486B (zh) 2020-11-03
CA2905359C (en) 2021-05-25
RU2015143466A (ru) 2017-04-18
DK3932932T3 (da) 2025-08-18
JP6530804B2 (ja) 2019-06-12
CA3114062A1 (en) 2014-10-02
HK1220375A1 (en) 2017-05-05
EP4643945A3 (en) 2026-01-14
JP7715692B2 (ja) 2025-07-30
EP2968369A4 (en) 2016-09-14
BR112015022174B1 (pt) 2022-07-05
IL241301A0 (en) 2015-11-30
DK3461834T3 (da) 2021-08-23
PT3932932T (pt) 2025-09-29
JP2016513663A (ja) 2016-05-16
AU2021200205A1 (en) 2021-03-18
AU2025203021A1 (en) 2025-05-22
SMT202100475T1 (it) 2021-09-14
AU2022279366B2 (en) 2025-02-06
EP2968369A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
SMT202100475T1 (it) Steroidi neuroattivi
ZA201506807B (en) Neuroactive steroids,compositions ,and uses thereof
PL3021852T3 (pl) Neuroaktywne steroidy, kompozycje i ich zastosowania
PT3488852T (pt) Esteroides neuroativos, composições e seus usos
PL3090813T3 (pl) Panel
SG11201508538SA (en) Complex
GB201306247D0 (en) Formwork Panel
PL3020229T3 (pl) Obsługa urządzeń o ograniczonym zasięgu
AU353247S (en) Single suite
PL2851472T3 (pl) Rama ustawcza
PL3044389T3 (pl) Konstrukcja słupkowo-ryglowa
SG11201506993TA (en) Tube-fastening structure
IL242777A (en) Building system elements
ZA201602197B (en) Panel assembly
AU350608S (en) Bracket
HUE047915T2 (hu) Takarópanel
GB201323006D0 (en) Panel
EP2979746A4 (en) STRUCTURE
PT3051152T (pt) Estrutura de ligação para peças de madeira
GB201310730D0 (en) New structure
GB201303947D0 (en) Bracket
GB2510875B (en) Bracket
TWM476536U (en) Easy-to-position bracket
GB201312389D0 (en) Panel
GB201311947D0 (en) Panel